Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD).

@article{Salazar2004DosedependentIO,
  title={Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD).},
  author={Robinson Salazar and Josep Tabernero and Federico G. A. Rojo and Eugenio Castillo Jim{\'e}nez and Isabel Montaner and Esther Casado and Gemma Sala and Joachim Tillner and Renuka Malik and Jos{\'e} Baselga},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={2002}
}
2002 Background: EMD 72000, an IgG1 humanized anti-EGFR MAb, has a prolonged half life and we showed that 1200q3w has favorable PK profile when compared to more frequent schedules (Tabernero et al, Proc ASCO 2003, abst 770). To define the OBD of q3w EMD 72000, we have now studied additional dose levels: 400, 800 and 1600 mg. METHODS Skin and tumor biopsies were performed at - 24 hrs and + 43 days of treatment. pEGFR, pMAPK, Ki67 and p27 were done by immunohistochemistry. RESULTS 51 patients… CONTINUE READING
11 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…